Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

NCT01888107 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

347

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder

Interventions

DRUG: Risperidone Long-acting Injectable (LAI) 25 mg
DRUG: Risperidone LAI 37.5 mg
DRUG: Risperidone LAI 50 mg

Sponsor

Janssen-Cilag S.p.A.